[144] Guardant Health, Inc. SEC Filing
Guardant Health, Inc. (GH) Form 144 shows a proposed Rule 144 sale and recent related transactions by insiders. The filer reports intent to sell 2,000 common shares through Charles Schwab with an aggregate market value of $123,510 and an approximate sale date of 08/21/2025 on NASDAQ. Those 2,000 shares were acquired on 10/01/2024 via the lapse of restricted stock as equity compensation. The filing also discloses a prior sale by Kumud Kalia of 4,000 shares on 06/03/2025 for gross proceeds of $185,562. The notice includes the standard insider representation regarding material undisclosed information and potential 10b5-1 plan disclosure.
Guardant Health, Inc. (GH) 鈥� Il Modulo 144 indica una vendita proposta ai sensi della Regola 144 e transazioni correlate recenti da parte di insider. Il dichiarante segnala l'intenzione di vendere 2.000 azioni ordinarie tramite Charles Schwab con un valore di mercato complessivo di $123.510 e una data di vendita approssimativa del 21/08/2025 sul NASDAQ. Le 2.000 azioni sono state acquisite il 01/10/2024 per effetto della scadenza di azioni vincolate concesse come compenso azionario. La comunicazione riporta inoltre una precedente vendita da parte di Kumud Kalia di 4.000 azioni il 03/06/2025 per un ricavo lordo di $185.562. L'avviso contiene la consueta dichiarazione dell'insider circa l'assenza di informazioni materiali non divulgate e la possibile presenza di un piano 10b5-1.
Guardant Health, Inc. (GH) 鈥� El Formulario 144 muestra una venta propuesta conforme a la Norma 144 y transacciones relacionadas recientes por parte de insiders. El declarante informa su intenci贸n de vender 2.000 acciones ordinarias a trav茅s de Charles Schwab por un valor de mercado agregado de $123.510 y una fecha aproximada de venta del 21/08/2025 en NASDAQ. Esas 2.000 acciones se adquirieron el 01/10/2024 por el vencimiento de acciones restringidas recibidas como compensaci贸n en acciones. El expediente tambi茅n revela una venta previa de Kumud Kalia de 4.000 acciones el 03/06/2025 por ingresos brutos de $185.562. La notificaci贸n incluye la representaci贸n est谩ndar del insider sobre la ausencia de informaci贸n material no divulgada y la posible existencia de un plan 10b5-1.
Guardant Health, Inc. (GH) 鈥� Form 144電� 攴滌箼 144鞐� 霐半ジ 鞓堨爼霅� 毵る弰 氚� 雮措秬鞛� 甏�霠� 斓滉芳 瓯半灅毳� 氤挫棳欷嶋媹雼�. 鞝滌稖鞚胳潃 Charles Schwab鞚� 韱淀暣 2,000 氤错喌欤�毳� 齑� $123,510鞚� 鞁滉皜搿� 毵る弰頃� 鞚橃偓鞕� NASDAQ鞐愳劀鞚� 鞓堨儊 毵る弰鞚检潉 2025-08-21搿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 2,000欤茧姅 2024-10-01鞐� 欤检嫕氤挫儊鞙茧 攵�鞐悳 鞝滍暅欤缄皜 靻岆└霅橂┐靹� 旆摑霅� 瓴冹瀰雼堧嫟. 鞝滌稖靹滊電� 霕愴暅 Kumud Kalia臧� 2025-06-03鞐� 4,000欤�毳� 毵る弰頃橃棳 齑濎垬鞚� $185,562毳� 鞓Π 靷嫟鞚� 瓿店皽頃╇媹雼�. 韱奠氍胳棎電� 欷戩殧 氙戈车臧� 鞝曤炒鞚� 攵�臁挫灛 氚� 10b5-1 頂岆灉 臧�電レ劚鞐� 甏�頃� 響滌 雮措秬鞛� 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Guardant Health, Inc. (GH) 鈥� Le formulaire 144 indique une vente projet茅e conform茅ment 脿 la r猫gle 144 et des transactions connexes r茅centes par des initi茅s. Le d茅clarant signale son intention de vendre 2 000 actions ordinaires via Charles Schwab pour une valeur de march茅 totale de 123 510 $ et une date de vente approximative fix茅e au 21/08/2025 sur le NASDAQ. Ces 2 000 actions ont 茅t茅 acquises le 01/10/2024 suite 脿 l'茅ch茅ance d'actions restreintes re莽ues en tant que r茅mun茅ration en actions. Le dossier divulgue 茅galement une vente ant茅rieure par Kumud Kalia de 4 000 actions le 03/06/2025 pour un produit brut de 185 562 $. L'avis inclut la d茅claration standard de l'initi茅 concernant l'absence d'informations mat茅rielles non divulgu茅es et la possibilit茅 d'un plan 10b5-1.
Guardant Health, Inc. (GH) 鈥� Das Formular 144 zeigt einen geplanten Verkauf nach Rule 144 und j眉ngste damit zusammenh盲ngende Transaktionen durch Insider. Der Einreicher gibt an, beabsichtigt zu sein, 2.000 Stammaktien 眉ber Charles Schwab mit einem gesamten Marktwert von $123.510 zu verkaufen und ein ungef盲hres Verkaufsdatum 21.08.2025 an der NASDAQ anzustreben. Diese 2.000 Aktien wurden am 01.10.2024 durch das Verfallen von eingeschr盲nkten Aktien als Aktienverg眉tung erworben. Die Einreichung offenbart au脽erdem einen fr眉heren Verkauf durch Kumud Kalia von 4.000 Aktien am 03.06.2025 mit Bruttoeinnahmen von $185.562. Die Mitteilung enth盲lt die 眉bliche Insidererkl盲rung hinsichtlich nicht offengelegter wesentlicher Informationen sowie eines m枚glichen 10b5-1-Plans.
- Full Rule 144 disclosure provided with acquisition dates, broker, and planned sale date indicating regulatory compliance
- Transaction transparency includes both the intended sale and a prior sale with gross proceeds, aiding investor visibility
- Insider selling activity (2,000 shares planned; 4,000 previously sold) could be viewed negatively by some investors as reduced insider ownership
Insights
TL;DR: Routine Rule 144 notice disclosing an insider sale of recently vested restricted shares and a prior sale by a named individual.
This filing documents compliance with Rule 144 for an intended sale of 2,000 shares acquired through a restricted stock lapse on 10/01/2024, to be executed via Charles Schwab on 08/21/2025. It also reports a separate, completed sale of 4,000 shares by Kumud Kalia on 06/03/2025 for $185,562. From a compliance perspective, the filing provides essential transaction dates, acquisition nature, and broker details required under Rule 144; no material undisclosed information is asserted by the seller.
TL;DR: Insider selling of vested equity is disclosed; context suggests routine liquidity rather than employment or control change.
The notice shows equity compensation vesting followed by a planned sale, which is a common executive/employment-related liquidity event. The designations and amounts are clear: 2,000 shares from restricted stock lapse and a prior 4,000-share sale. The filing includes the standard attestation about no material nonpublic information and mention of potential 10b5-1 plans, indicating awareness of trading-plan safe harbors.
Guardant Health, Inc. (GH) 鈥� Il Modulo 144 indica una vendita proposta ai sensi della Regola 144 e transazioni correlate recenti da parte di insider. Il dichiarante segnala l'intenzione di vendere 2.000 azioni ordinarie tramite Charles Schwab con un valore di mercato complessivo di $123.510 e una data di vendita approssimativa del 21/08/2025 sul NASDAQ. Le 2.000 azioni sono state acquisite il 01/10/2024 per effetto della scadenza di azioni vincolate concesse come compenso azionario. La comunicazione riporta inoltre una precedente vendita da parte di Kumud Kalia di 4.000 azioni il 03/06/2025 per un ricavo lordo di $185.562. L'avviso contiene la consueta dichiarazione dell'insider circa l'assenza di informazioni materiali non divulgate e la possibile presenza di un piano 10b5-1.
Guardant Health, Inc. (GH) 鈥� El Formulario 144 muestra una venta propuesta conforme a la Norma 144 y transacciones relacionadas recientes por parte de insiders. El declarante informa su intenci贸n de vender 2.000 acciones ordinarias a trav茅s de Charles Schwab por un valor de mercado agregado de $123.510 y una fecha aproximada de venta del 21/08/2025 en NASDAQ. Esas 2.000 acciones se adquirieron el 01/10/2024 por el vencimiento de acciones restringidas recibidas como compensaci贸n en acciones. El expediente tambi茅n revela una venta previa de Kumud Kalia de 4.000 acciones el 03/06/2025 por ingresos brutos de $185.562. La notificaci贸n incluye la representaci贸n est谩ndar del insider sobre la ausencia de informaci贸n material no divulgada y la posible existencia de un plan 10b5-1.
Guardant Health, Inc. (GH) 鈥� Form 144電� 攴滌箼 144鞐� 霐半ジ 鞓堨爼霅� 毵る弰 氚� 雮措秬鞛� 甏�霠� 斓滉芳 瓯半灅毳� 氤挫棳欷嶋媹雼�. 鞝滌稖鞚胳潃 Charles Schwab鞚� 韱淀暣 2,000 氤错喌欤�毳� 齑� $123,510鞚� 鞁滉皜搿� 毵る弰頃� 鞚橃偓鞕� NASDAQ鞐愳劀鞚� 鞓堨儊 毵る弰鞚检潉 2025-08-21搿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 2,000欤茧姅 2024-10-01鞐� 欤检嫕氤挫儊鞙茧 攵�鞐悳 鞝滍暅欤缄皜 靻岆└霅橂┐靹� 旆摑霅� 瓴冹瀰雼堧嫟. 鞝滌稖靹滊電� 霕愴暅 Kumud Kalia臧� 2025-06-03鞐� 4,000欤�毳� 毵る弰頃橃棳 齑濎垬鞚� $185,562毳� 鞓Π 靷嫟鞚� 瓿店皽頃╇媹雼�. 韱奠氍胳棎電� 欷戩殧 氙戈车臧� 鞝曤炒鞚� 攵�臁挫灛 氚� 10b5-1 頂岆灉 臧�電レ劚鞐� 甏�頃� 響滌 雮措秬鞛� 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Guardant Health, Inc. (GH) 鈥� Le formulaire 144 indique une vente projet茅e conform茅ment 脿 la r猫gle 144 et des transactions connexes r茅centes par des initi茅s. Le d茅clarant signale son intention de vendre 2 000 actions ordinaires via Charles Schwab pour une valeur de march茅 totale de 123 510 $ et une date de vente approximative fix茅e au 21/08/2025 sur le NASDAQ. Ces 2 000 actions ont 茅t茅 acquises le 01/10/2024 suite 脿 l'茅ch茅ance d'actions restreintes re莽ues en tant que r茅mun茅ration en actions. Le dossier divulgue 茅galement une vente ant茅rieure par Kumud Kalia de 4 000 actions le 03/06/2025 pour un produit brut de 185 562 $. L'avis inclut la d茅claration standard de l'initi茅 concernant l'absence d'informations mat茅rielles non divulgu茅es et la possibilit茅 d'un plan 10b5-1.
Guardant Health, Inc. (GH) 鈥� Das Formular 144 zeigt einen geplanten Verkauf nach Rule 144 und j眉ngste damit zusammenh盲ngende Transaktionen durch Insider. Der Einreicher gibt an, beabsichtigt zu sein, 2.000 Stammaktien 眉ber Charles Schwab mit einem gesamten Marktwert von $123.510 zu verkaufen und ein ungef盲hres Verkaufsdatum 21.08.2025 an der NASDAQ anzustreben. Diese 2.000 Aktien wurden am 01.10.2024 durch das Verfallen von eingeschr盲nkten Aktien als Aktienverg眉tung erworben. Die Einreichung offenbart au脽erdem einen fr眉heren Verkauf durch Kumud Kalia von 4.000 Aktien am 03.06.2025 mit Bruttoeinnahmen von $185.562. Die Mitteilung enth盲lt die 眉bliche Insidererkl盲rung hinsichtlich nicht offengelegter wesentlicher Informationen sowie eines m枚glichen 10b5-1-Plans.
FAQ
What does Guardant Health's Form 144 disclose for GH?
How were the 2,000 shares acquired per the Form 144?
Were there any recent related sales reported?
Which broker is handling the proposed sale?
Does the filer state there is any undisclosed material information?
